WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	74.62B
Revenue (ttm)	4.31B
Net Income (ttm)	1.14B
Shares Out	1.20B
EPS (ttm)	0.88
PE Ratio	70.14
Forward PE	47.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,077,509
Average Volume	6,886,569
Open	62.60
Previous Close	61.95
Day's Range	61.55 - 63.95
52-Week Range	17.20 - 63.30
Beta	n/a
RSI	66.07
Earnings Date	Aug 18, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China....

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,041
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY